Literature DB >> 25876612

Immunogenicity to infliximab is associated with HLA-DRB1.

Thomas Billiet1, Niels Vande Casteele2, Thomas Van Stappen2, Fred Princen3, Sharat Singh3, Ann Gils2, Marc Ferrante4, Gert Van Assche4, Isabelle Cleynen4, Severine Vermeire4.   

Abstract

Entities:  

Keywords:  HLA GENES; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INFLIXIMAB

Mesh：

Substances：

Year:  2015        PMID： 25876612     DOI： 10.1136/gutjnl-2015-309698

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  17 in total

Review 1.  Resolution of Crohn's disease.

Authors:  Heike Schmitt; Clemens Neufert; Markus F Neurath; Raja Atreya
Journal:  Semin Immunopathol       Date:  2019-09-24       Impact factor: 9.623

Review 2.  Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.

Authors:  Pieter Hindryckx; Gregor Novak; Niels Vande Casteele; Reena Khanna; Debby Laukens; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 3.  Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients.

Authors:  Jørgen Jahnsen
Journal:  Therap Adv Gastroenterol       Date:  2016-03-21       Impact factor: 4.409

4.  How to approach understanding complex trait genetics - inflammatory bowel disease as a model complex trait.

Authors:  Isabelle Cleynen; Jonas Halfvarsson
Journal:  United European Gastroenterol J       Date:  2019-12-01       Impact factor: 4.623

Review 5.  Use of anti-TNF drug levels to optimise patient management.

Authors:  Konstantinos Papamichael; Adam S Cheifetz
Journal:  Frontline Gastroenterol       Date:  2016-02-26

6.  Comparison of Timing to Develop Anti-Drug Antibodies to Infliximab and Adalimumab Between Adult and Pediatric Age Groups, Males and Females.

Authors:  Maria Consiglia Trotta; Roberto Alfano; Giovanna Cuomo; Ciro Romano; Antonietta Gerarda Gravina; Marco Romano; Marilena Galdiero; Maria Vittoria Montemurro; Antonio Giordano; Michele D'Amico
Journal:  J Pediatr Pharmacol Ther       Date:  2021-12-22

Review 7.  Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.

Authors:  Uri Kopylov; Ernest Seidman
Journal:  Therap Adv Gastroenterol       Date:  2016-04-01       Impact factor: 4.409

8.  Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature.

Authors:  Mansi M Kothari; Douglas L Nguyen; Nimisha K Parekh
Journal:  World J Gastrointest Pharmacol Ther       Date:  2017-08-06

9.  Identification of HLA-DRB1 association to adalimumab immunogenicity.

Authors:  Mohan Liu; Jacob Degner; Justin Wade Davis; Kenneth B Idler; Ahmed Nader; Nael M Mostafa; Jeffrey F Waring
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

Review 10.  Genome-wide association studies in Crohn's disease: Past, present and future.

Authors:  Bram Verstockt; Kenneth Gc Smith; James C Lee
Journal:  Clin Transl Immunology       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.